Ultomiris: Entering the European IgAN Market as A Potential Therapy Option

The European IgAN market circulated mostly digital promotional materials, which exclusively targeted German and Italian healthcare professionals. Regeneron focused on the company’s commitment to rare diseases, while AstraZeneca’s Ultomiris promoted a digital series and the brand’s multiple benefits to improve the patient’s quality of life.